OPKO Health’s (OPK) Buy Rating Reaffirmed at HC Wainwright

OPKO Health (NASDAQ:OPK)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a report issued on Wednesday,Benzinga reports. They presently have a $3.00 price target on the biotechnology company’s stock. HC Wainwright’s price target would indicate a potential upside of 98.68% from the stock’s current price.

OPK has been the topic of a number of other research reports. Piper Sandler restated an “overweight” rating and issued a $3.00 target price on shares of OPKO Health in a research note on Tuesday, September 17th. StockNews.com raised OPKO Health from a “sell” rating to a “hold” rating in a report on Tuesday. Finally, Barrington Research reiterated an “outperform” rating and issued a $2.25 price target on shares of OPKO Health in a report on Friday, November 8th.

OPKO Health Stock Up 4.1 %

Shares of NASDAQ:OPK opened at $1.51 on Wednesday. The firm has a market cap of $1.03 billion, a PE ratio of -7.95 and a beta of 1.63. The company has a fifty day simple moving average of $1.55 and a 200 day simple moving average of $1.50. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30. OPKO Health has a 12-month low of $0.86 and a 12-month high of $1.76.

Insider Buying and Selling

In other news, CEO Phillip Md Et Al Frost purchased 500,000 shares of OPKO Health stock in a transaction dated Wednesday, December 11th. The stock was bought at an average price of $1.56 per share, with a total value of $780,000.00. Following the completion of the acquisition, the chief executive officer now owns 212,411,477 shares in the company, valued at $331,361,904.12. The trade was a 0.24 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have acquired a total of 1,304,255 shares of company stock worth $2,024,605 over the last quarter. 47.26% of the stock is owned by company insiders.

Institutional Trading of OPKO Health

Hedge funds have recently bought and sold shares of the company. CIBC Asset Management Inc increased its stake in shares of OPKO Health by 79.1% in the second quarter. CIBC Asset Management Inc now owns 20,322 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 8,978 shares during the period. FMR LLC grew its holdings in OPKO Health by 103.6% in the 3rd quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock worth $32,000 after buying an additional 11,089 shares in the last quarter. Orion Portfolio Solutions LLC bought a new position in OPKO Health in the 3rd quarter worth approximately $45,000. Algert Global LLC acquired a new stake in OPKO Health in the 2nd quarter valued at approximately $44,000. Finally, Private Advisor Group LLC boosted its position in OPKO Health by 242.7% during the 3rd quarter. Private Advisor Group LLC now owns 35,301 shares of the biotechnology company’s stock worth $53,000 after acquiring an additional 25,000 shares during the period. 64.63% of the stock is currently owned by institutional investors.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.